Vesugen
Bioregulator tripeptide
Synthetic bioregulator tripeptide Lys-Glu-Asp, described as a vascular-endothelium peptide, studied for gene-expression effects in cell culture.
Evidence level. Evidence comes mainly from animal or other preclinical models. About the badges
- Class
- Bioregulator tripeptide
- Category
- Bioregulator Peptides
- Type
- Single compound
- Development and regulatory status
- Not approved by FDA or EMA, research-only bioregulator peptide
What researchers study
Synthetic tripeptide Lys-Glu-Asp (KED) from the Khavinson programme, described as a vascular-endothelium peptide. Reported to alter endothelial and ageing-related gene expression in cell culture; evidence is mostly cell work from one research network.
Research areas
- Endothelial cell proliferation and ageing markers in culture
- Atherosclerotic and restenotic endothelium models in vitro
- Neuronal differentiation markers in stem cells
- Biological-age markers in small human studies
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- cell culture
In an in vitro endothelium model, KED normalised endothelin-1 expression raised in atherosclerotic and restenotic cells and increased sirtuin-1 and connexin expression
- cell culture
KED restored the proliferation marker Ki-67 that falls with ageing in endothelial and tissue cultures, and docking suggested contact with the MKI67 promoter
- small human study
A small Russian study of 32 people found anabolic marker changes with Vesugen and Pinealon, but also pro-oxidant activity and fewer CD34+ cells
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
